PMID- 9574843
OWN - NLM
STAT- MEDLINE
DCOM- 19980618
LR  - 20190914
IS  - 0143-4179 (Print)
IS  - 0143-4179 (Linking)
VI  - 31
IP  - 1
DP  - 1997 Feb
TI  - Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus 
      accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry.
PG  - 82-8
AB  - Differential pulse voltammetry was used to investigate the extracellular dopamine 
      (DA) and DOPAC signal in the anterior part of nucleus accumbens (N.acc.) after 
      microinjection of cholecystokinin (CCK) derivatives into the ventral tegmental 
      area (VTA). Both the mixed CCK(A)/CCK(B) receptor agonist CCK-8s and the 
      selective CCK(B) receptor agonist CCK-4 caused a dose-dependent increase in the 
      DA signal after doses of 10 ng and 100 ng while CCK-8s had no effect on the DOPAC 
      signal. The CCK(A) receptor antagonist L 364,718 (25 microg/kg i.p.) as well as 
      the CCK(B) receptor antagonist L 365,260 (25 microg/kg i.p.) were administered 
      prior to microinjection of 100 ng CCK-8s and L 365,260, but not L 364,718, 
      completely inhibiting the DA increase produced by CCK-8s. Analysis of the tissue 
      levels of DA and its main metabolites in the anterior part of N.acc. revealed no 
      changes after CCK-8s microapplication into VTA. The presented data indicate a 
      CCK(B) receptor-mediated increase in extracellular DA in the anterior N.acc. 
      after microapplication of CCK derivatives into the VTA.
FAU - Reum, T
AU  - Reum T
AD  - Institute of Pharmacology and Toxicology, Medical Faculty (Charite), 
      Humboldt-University at Berlin, Germany.
FAU - Schafer, U
AU  - Schafer U
FAU - Marsden, C A
AU  - Marsden CA
FAU - Fink, H
AU  - Fink H
FAU - Morgenstern, R
AU  - Morgenstern R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Neuropeptides
JT  - Neuropeptides
JID - 8103156
RN  - 0 (8-sulfocholecystokinin octapeptide)
RN  - 0 (Benzodiazepinones)
RN  - 0 (Hormone Antagonists)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Receptor, Cholecystokinin A)
RN  - 0 (Receptor, Cholecystokinin B)
RN  - 0 (Receptors, Cholecystokinin)
RN  - 0OL293AV80 (Tetragastrin)
RN  - 370JHF4586 (L 365260)
RN  - 9011-97-6 (Cholecystokinin)
RN  - 9MV14S8G3E (Pargyline)
RN  - JE6P7QY7NH (Devazepide)
RN  - M03GIQ7Z6P (Sincalide)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Benzodiazepinones/pharmacology
MH  - Cholecystokinin/*pharmacology
MH  - Devazepide
MH  - Dopamine/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Electrophysiology
MH  - Extracellular Space/metabolism
MH  - Hormone Antagonists/pharmacology
MH  - Male
MH  - Microinjections
MH  - Monoamine Oxidase Inhibitors/pharmacology
MH  - Nucleus Accumbens/chemistry/*metabolism
MH  - Pargyline/pharmacology
MH  - *Phenylurea Compounds
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Cholecystokinin A
MH  - Receptor, Cholecystokinin B
MH  - Receptors, Cholecystokinin/agonists/antagonists & inhibitors/*metabolism
MH  - Sincalide/analogs & derivatives/pharmacology
MH  - Tetragastrin/pharmacology
MH  - Ventral Tegmental Area/chemistry/*metabolism
EDAT- 1997/02/01 00:00
MHDA- 1998/05/09 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1998/05/09 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - S0143-4179(97)90025-1 [pii]
AID - 10.1016/s0143-4179(97)90025-1 [doi]
PST - ppublish
SO  - Neuropeptides. 1997 Feb;31(1):82-8. doi: 10.1016/s0143-4179(97)90025-1.